Results 111 to 120 of about 1,239,345 (193)

Enigmatic Roles of Complement Anaphylatoxin Signaling in Health and Disease. [PDF]

Immune Netw
Shadid A, Hok KD, Domozhirov AY, Weng-Mills T, Doursout MF, Banda NK, Restrepo MI, Shivshankar P.   +7 more
europepmc   +1 more source

Intratumoral C3ar/C5ar1 Antagonists Imbedded in an In Situ Forming Implant Can Robustly Suppress Solid Tumors. [PDF]

Cells
Choi YA, Konrad R, Pohlmann ES, Abenojar E, Exner A, Medof ME.   +5 more
europepmc   +1 more source

Complement system in cancer: friend or foe of immunotherapy. [PDF]

J Immunother Cancer
Shah HK, Prem S, Wu X, Liszewski MK, Atkinson JP, Singh AK, Kapoor V.   +6 more
europepmc   +1 more source

Complement C5a receptor 1 antagonist attenuates alveolar hypoplasia induced by pulmonary hypoperfusion and its underlying mechanisms. [PDF]

Front Immunol
Liu C, Zheng S, Wang Y, Wang Z, Li D, Li H, Xue Y, Wang Z, She S, Ye L, Ruan P, Fu L, Sun Q.   +12 more
europepmc   +1 more source

The Role of Complement Anaphylatoxins (C3a and C5a) in Non-small Cell Lung Cancer: A Systematic Review. [PDF]

Cureus
Skarentzos K, Karagialani DK, Mitros V, Economopoulou P, Foukas P.   +4 more
europepmc   +1 more source

Dual role of complement in neuronal repair. [PDF]

Front Immunol
Lukomska A, Ciesielski P, Ratajczak MZ, Kucia M.   +3 more
europepmc   +1 more source

The Pleiotropic Effect of Complement C5a-C5aR1 Pathway in Diseases: From Immune Regulation to Targeted Therapy. [PDF]

Int J Mol Sci
Xu B, Zhou Z, Xiao Y, Liu Q, Xiao T, Lv Z, Wang H.   +6 more
europepmc   +1 more source

New Anticomplement Drugs in Nephrology: Mechanism and Indication.

Kidney Blood Press Res
Macciò L, Russo E, Costigliolo F, Battaglia Y, Viazzi F, Esposito P.   +5 more
europepmc   +1 more source

Complement dysregulation during the early phases of synucleinopathy. [PDF]

Acta Neuropathol
Khan H, Gifford M, Kordbacheh A, Bury A, Panoushek S, Cole-Strauss A, Kemp CJ, Luk KC, Steece-Collier K, Kuhn NC, Kanaan NM, Sortwell CE, Patterson JR, Benskey MJ.   +13 more
europepmc   +1 more source

Targeting C5AR1 disrupts complement-driven G0-phase maintenance and overcomes metabolic drug resistance in glioma. [PDF]

J Transl Med
Qian Y, Zhao K.
europepmc   +1 more source